Cancer


FDA Approval For RET Cancer Drug Gavreto

Recently FDA Okayed Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer. Gavreto approved under the FDA’s accelerated approval…









HER2-Positive Breast Cancer

The key of abemaciclib, fulvestrant, and trastuzumab revealed a significant rise in progression-free survival (PFS) versus standard-of-care chemotherapy plus trastuzumab while giving a tolerable safety…